Objective
Drug resistance (DR) in Leishmania is a growing clinical challenge, yet often viewed too simplistically, overlooking the diversity of drug responses and survival strategies. Drug sensitivity (DS) and persistence are among these neglected responses, though essential for optimizing treatment: DS and DR reveal collateral sensitivities, while persistence, a dormant, slow- or non-growing drug response state, could drive treatment relapse. This means persistence enables survival during therapy and regrowth once drug pressure subsides, a state considered a transient, non-genetic adaptation entered stochastically or by stress. However, growing evidence, including our prior work, supports the hypothesis that specific mutations and other genomic pre-adaptations can alter the frequency of parasite subpopulations entering a persister state, challenging its classical genetic separation from DR and DS.
In PERSIST we will test this hypothesis by combining in vitro and in vivo genome-wide CRISPR cytosine base-editing loss-of-function screens developed by my group with persister-labelling and drug-treatment approaches to systematically map the genetic determinants of DS, DR, and persistence in mammalian-stage Leishmania amastigotes. Additionally, using lineage-tracing screens with barcoded parasite populations, we will test whether stochastic and stress-induced persisters exhibit a “memory effect” that predisposes subpopulations toward persistence. Finally, mutants and cell lines with altered persistence frequency will be tested for in vivo survival in sand flies and host niches, and profiled at transcriptomic, epigenetic, and metabolomic levels to uncover key persistence mechanisms.
By revealing the genomic and functional basis of persistence and integrating it with DR and DS, PERSIST will transform our understanding of Leishmania drug response, guide new combination therapies for the neglected tropical disease leishmaniasis, and provide insights into persistence across pathogens.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences tropical medicine
- medical and health sciences clinical medicine allergology drug allergy
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- natural sciences biological sciences genetics mutation
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2026-STG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
97070 Wuerzburg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.